Indantadol

Indantadol (the free base of CHF-3381) is an orally active, non-selective NMDA antagonist and MAO inhibitor. Indantadol blocks the binding of [³H]-MK-801 to NMDA receptors in a non-competitive manner, with an IC50 of 8.1 μM. Indantadol completely inhibits dopamine release caused by NMDA. Indantadol protects neurons, with an ED₅₀ of 35 μM. Indantadol has anticonvulsant and anti-high pain hypersensitivity activities[1][2][3].

Product Specifications

CAS Number

[202844-10-8]

Product Name Alternative

CHF-3381 (free base)

UNSPSC

12352005

Hazard Statement

H315-H319-H320

Target

IGluR; Monoamine Oxidase

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Field of Research

Neurological Disease

Smiles

O=C(N)CNC1CC2=C(C=CC=C2)C1

Molecular Formula

C11H14N2O

Molecular Weight

190.24

Precautions

P264-P280-P302+P352-P305+P351+P338-P362

References & Citations

[1]Silvia Zucchini, et al. Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist. Neuroreport. 2022, 13, 6.|[2]Mattia C, Coluzzi F. Indantadol, a novel NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain. IDrugs. 2007 Sep;10 (9) :636-44. |[3]Gandolfi O, et al. Anticonvulsant preclinical profile of CHF 3381: dopaminergic and glutamatergic mechanisms. Pharmacol Biochem Behav. 2001 Sep;70 (1) :157-66.